Abstract Objective To study the clinical effect of early or late administration of caffeine citrate in the prevention and treatment of apnea in very low birth weight (VLBW) infants.Methods A total of 82 VLBW infants who were hospitalized and treated in the neonatal intensive care unit between June 2015 and May 2017 were enrolled. According to the age in days when caffeine citrate treatment was started, they were divided into early treatment group (< 3 days) with 22 infants and late treatment group (3- < 10 days) with 60 infants. A retrospective analysis was performed for their clinical data. The two groups were compared in terms of general information during the perinatal period, treatment process, and clinical outcome.Results Compared with the late treatment group, the early treatment group had a significantly lower birth weight (P=0.004), significantly shorter durations of mechanical ventilation and oxygen inhalation (P < 0.05), and a significantly lower incidence rate of bronchopulmonary dysplasia (P=0.032). There were no significant differences in other general information, treatment process, and clinical outcome between the two groups (P > 0.05).Conclusions Early administration of caffeine citrate can improve the prognosis of VLBW infants.
FENG Yun,CHENG Rui,ZHAO Li et al. Clinical effect of early or late administration of caffeine citrate in prevention and treatment of apnea in very low birth weight infants[J]. CJCP, 2018, 20(12): 979-984.
FENG Yun,CHENG Rui,ZHAO Li et al. Clinical effect of early or late administration of caffeine citrate in prevention and treatment of apnea in very low birth weight infants[J]. CJCP, 2018, 20(12): 979-984.
Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2010 update[J]. Neonatology, 2010, 97(4):402-417.
[2]
Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2013 update[J]. Neonatology, 2013, 103(4):353-368.
[3]
Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity[J]. N Engl J Med, 2006, 354(20):2112-2121.
[4]
Dobson NR, Patel RM, Smith PB, et al. Trends in caffeine use and association between clinical outcomes and timing of therapy in very low birth weight infants[J]. J Pediatr, 2014, 164(5):992-998.
[5]
Taha D, Kirkby S, Nawab U, et al. Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants[J]. J Matern Fetal Neonatal Med, 2014, 27(16):1698-1702.
[6]
Lodha A, Seshia M, McMillan DD, et al. Association of early caffeine administration and neonatal outcomes in very preterm neonates[J]. JAMA Pediatr, 2015, 169(1):33-38.
[7]
Patel RM, Leong T, Carlton DP, et al. Early caffeine therapy and clinical outcomes in extremely preterm infants[J]. J Perinatol, 2013, 33(2):134-140.
[8]
Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome -2016 update[J]. Neonatology, 2017, 111(2):107-125.
Spitzer AR. Evidence-based methylxanthine use in the NICU[J]. Clin Perinatol, 2012, 39(1):137-148.
[15]
Bauer J, Maier K, Linderkamp O, et al. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea[J]. Pediatrics, 2001, 107(4):660-663.
[16]
Bohrer B, Silveira RC, Neto EC, et al. Mechanical ventilation of newborns infant changes in plasma pro-and anti-inflammatory cytokines[J]. J Pediatr, 2010, 156(1):16-19.
[17]
Kim BI, Lee HE, Choi CW, et al. Increase in cord blood soluble E-selectin and tracheal aspirate neutrophils at birth and the development of new bronchopulmonary dysplasia[J]. J Perinat Med, 2004, 32(3):282-287.
[18]
Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity[J]. N Engl J Med, 2007, 357(19):1893-1902.
[19]
Hoecker C, Nelle M, Poeschl J, et al. Caffeine impairs cerebral and intestinal blood flow velocity in preterm infants[J]. Pediatrics, 2002, 109(5):784-787.
[20]
Tracy MB, Klimek J, Hinder M, et al. Does caffeine impair cerebral oxygenation and blood flow velocity in preterm infants?[J]. Acta Paediatr, 2010, 99(9):1319-1323.
[21]
Kilicdag H, Daglioglu YK, Erdogan S, et al. Effects of caffeine on neuronal apoptosis in neonatal hypoxic-ischemic brain injury[J]. J Matern Fetal Neonatal Med, 2014, 27(14):1470-1475.
[22]
Doyle LW, Cheong J, Hunt RW, et al. Caffeine and brain development in very preterm infants[J]. Ann Neurol, 2010, 68(5):734-742.
[23]
Soloveychik V, Bin-Nun A, Ionchev A, et al. Acute hemodynamic effects of caffeine administration in premature infants[J]. J Perinatol, 2009, 29(3):205-208.
[24]
Gillot I, Gouyon JB, Guignard JP. Renal effects of caffeine in preterm infants[J]. Biol Neonate, 1990, 58(3):133-136.
[25]
Blaustein MP, Golovina VA, Song H, et al. Organization of Ca2+ stores in vascular smooth muscle:functional implications[J]. Novartis Found Symp, 2002, 246:125-141.
[26]
Whorton AR, Collawn JB, Montgomery ME, et al. Arachidonic acid metabolism in cultured aortic endothelial cells. Effect of cAMP and 3-isobutyl-1-methylxanthine[J]. Biochem Pharmacol, 1985, 34(1):119-123.
[27]
Di Fiore JM, Kaffashi F, Loparo K, et al. The relationship between patterns of intermittent hypoxia and retinopathy of prematurity in preterm infants[J]. Pediatr Res, 2012, 72(6):606-612.
[28]
Bauer J, Maier K, Linderkamp O, et al. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea[J]. Pediatrics, 2001, 107(4):660-663.
[29]
Hoecker C, Nelle M, Poeschl J, et al. Caffeine impairs cerebral and intestinal blood flow velocity in preterm infants[J]. Pediatrics, 2002, 109(5):784-787.
[30]
Guthrie SO, Gordon PV, Thomas V, et al. Necrotizing enterocolitis among neonates in the United States[J]. J Perinatol, 2003, 23(4):278-285.
